Abstract:SARS-CoV-2 specific IgG responses play critical roles for patients to recover from COVID-19, in-depth dissecting of the IgG responses on systems level is of great interest. Herein, we adopted a newly developed high-throughput epitope mapping technology (AbMap), analyzed 55 COVID-19 convalescent sera and 226 antibody samples enriched by specific proteins or peptides from these sera. We revealed three areas that are rich of IgG epitopes, two are on Spike protein but outside of RBD, and one is on Nucleocapsid protein. We identified 29 significant epitopes on Spike protein, from two of these significant epitopes, two critical epitope residues were found, i. e ., D936 and P1263, which are highly related to the infectivity of SARS-CoV-2 In summary, we provided the first global map of IgG binding epitopes for SARS-CoV-2 at single amino acid resolution. This map will facilitate the precise development of therapeutic antibodies and vaccines. HIGHLIGHTS 1. A map of SARS-CoV-2 specific IgG binding epitopes at single amino acid resolution 2. Two areas outside of RBD that are rich of significant epitopes were identified 3. One area rich of significant epitopes was determined on Nucleocapsid protein 4. Two critical epitope residues (D936 and P1263) on Spike protein are highly related to the infectivity of SARS-CoV-2 ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was partially supported by National Key Research and Development Program of China Grant (No. 2016YFA0500600), National Natural Science Foundation of China (No. 31970130, 31670831, 31370813 and 31501054), Open Foundation of Key Laboratory of Systems Biomedicine (No. KLSB2020QN-05). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Institutional Ethics Review Committee of Foshan Fourth Hospital, Foshan, China. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data supporting the findings of this study could be found within the paper and its Supplementary information, and are available from the related databases. The raw data of NGS were deposited in the NCBI SRA Archive (https://www.ncbi.nlm.nih.gov/sra) with BioProject accession number: PRJNA660911. The raw data of peptide microarray were deposited in the Protein Microarray Database (PMD) (http://www.proteinmicroarray.cn/) with experiment accession number: PMDE246.

Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines Against COVID-19

The immunodominant and neutralization linear epitopes for SARS-CoV-2

Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients

Identification of Three Conserved Linear B Cell Epitopes on the SARS-CoV-2 Spike Protein

Mapping Cross-Variant Neutralizing Sites on the SARS-CoV-2 Spike Protein.

Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2

Identification and Characterization of Novel Neutralizing Epitopes in the Receptor-Binding Domain of SARS-CoV Spike Protein: Revealing the Critical Antigenic Determinants in Inactivated SARS-CoV Vaccine.

Methods to Identify Immunogenic Peptides in SARS‐CoV‐2 Spike and Protective Monoclonal Antibodies in COVID‐19 Patients

A key linear epitope for a potent neutralizing antibody to SARS CoV 2 S RBD

Computational epitope map of SARS-CoV-2 spike protein

Systematic profiling of SARS CoV 2 specific IgG epitopes at single amino acid resolution

Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients

T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.

Functional Mapping of B-cell Linear Epitopes of SARS-CoV-2 in COVID-19 Convalescent Population.

Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies

Functional Mapping of B-cell Linear Epitopes of SARS-CoV-2 in COVID-19 Convalescent Population

Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes

Longitudinal and proteome-wide analyses of antibodies in COVID-19 patients reveal features of the humoral immune response to SARS-CoV-2

Identification of Four Linear B-cell Epitopes on the SARS-CoV-2 Spike Protein Able to Elicit Neutralizing Antibodiesidentification of Four Linear B-cell Epitopes on the SARS-CoV-2 Spike Protein Able to Elicit Neutralizing Antibodies

Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen

Epitope-based peptide vaccine design and target site characterization against novel coronavirus disease caused by SARS-CoV-2